Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ex-vivo Delivery of Rituximab to Prevent Post-transplant Lymphoproliferative Disease in Epstein-Barr Virus Mismatch Lung Transplant Recipients: A Pilot Trial

NCT04507477 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04507477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04507477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ex-vivo Delivery of Rituximab to Prevent Post-transplant Lymphoproliferative Disease in Epstein-Barr Virus Mismatch Lung Transplant Recipients: A Pilot Trial
Lead sponsor
University Health Network, Toronto
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 7, 2020
Completion date
February 7, 2023
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus infections, post-transplant lymphoproliferative disorder